Vifor Pharma AG
SIX:VIFN
Vifor Pharma AG
Revenue
Vifor Pharma AG
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
V
|
Vifor Pharma AG
SIX:VIFN
|
Revenue
CHf1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-7%
|
Novartis AG
SIX:NOVN
|
Revenue
$46.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Roche Holding AG
SIX:ROG
|
Revenue
CHf58.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Revenue
$9.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vifor Pharma AG's Revenue?
Revenue
1.8B
CHF
Based on the financial report for Dec 31, 2021, Vifor Pharma AG's Revenue amounts to 1.8B CHF.
What is Vifor Pharma AG's Revenue growth rate?
Revenue CAGR 10Y
-7%
Over the last year, the Revenue growth was 3%. The average annual Revenue growth rates for Vifor Pharma AG have been 3% over the past three years , 8% over the past five years , and -7% over the past ten years .